TET2 and acute myeloid leukemia: Finally, NPM1-mutated AML harboring concomitant clonal hematopoiesis driven mutations (e.g., DNMT3A, TET2) showed an enriched tumor inflammation signature score, predicting a clinical benefit from anti-PD-1 treatment [130].